--- title: "GRI Bio | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286312022.md" datetime: "2026-05-13T20:23:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286312022.md) - [en](https://longbridge.com/en/news/286312022.md) - [zh-HK](https://longbridge.com/zh-HK/news/286312022.md) --- # GRI Bio | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -1.61. EBIT: As of FY2026 Q1, the actual value is USD -2.008 M, beating the estimate of USD -2.4 M. GRI Bio, Inc. operates within one reportable segment: biotechnology research, focusing on the research and development of products for inflammatory diseases . #### Operating Results (Three Months Ended March 31) - **Research and Development Expenses:** For the three months ended March 31, 2026, Research and Development Expenses were $361 thousand, a decrease from $1,640 thousand for the same period in 2025 . This $1.2 million decrease was primarily due to a $1.1 million reduction in expenses related to the GRI-0621 registration development program following the completion of its Phase 2a clinical trial, and a $0.1 million decrease in consulting fees . - **General and Administrative Expenses:** These expenses increased to $1,642 thousand for the three months ended March 31, 2026, from $1,411 thousand for the same period in 2025 . The $0.2 million increase was mainly due to a $0.4 million rise in public company expenses, partially offset by a $0.1 million decrease in personnel expenses, including stock-based compensation . - **Total Operating Expenses:** Total operating expenses were $2,003 thousand for the three months ended March 31, 2026, down from $3,051 thousand for the same period in 2025 . - **Loss from Operations:** The company reported a loss from operations of - $2,003 thousand for the three months ended March 31, 2026, compared to - $3,051 thousand for the three months ended March 31, 2025 . - **Interest Income:** Interest income remained consistent at $5 thousand for both the three months ended March 31, 2026, and 2025 . - **Net Loss:** The net loss for the three months ended March 31, 2026, was - $1,998 thousand, an improvement from - $3,046 thousand for the same period in 2025 . #### Liquidity and Capital Resources - **Cash and Cash Equivalents:** As of March 31, 2026, GRI Bio, Inc. had $11.0 million in cash and cash equivalents . - **Accumulated Deficit:** The accumulated deficit reached $53.7 million as of March 31, 2026 . - **Cash Used in Operating Activities:** Cash used in operating activities increased to - $3,685 thousand for the three months ended March 31, 2026, from - $1,736 thousand for the same period in 2025 . This $1.9 million increase was primarily driven by a $1.8 million increase in cash used for accounts payable and a $0.9 million increase in cash used for accrued expenses, partially offset by a $1.0 million decrease in net loss . - **Cash Provided by (Used in) Financing Activities:** Net cash provided by financing activities was $6,504 thousand for the three months ended March 31, 2026, primarily from $6.8 million in proceeds from the At The Market (ATM) Offering, offset by $0.3 million in stock issuance costs . In contrast, the company used - $11 thousand in financing activities for the three months ended March 31, 2025 . - **Net Increase (Decrease) in Cash and Cash Equivalents:** There was a net increase of $2,819 thousand in cash and cash equivalents for the three months ended March 31, 2026, compared to a net decrease of - $1,747 thousand for the same period in 2025 . #### Future Outlook and Strategy GRI Bio, Inc. expects its current cash and cash equivalents to fund planned operating expenses and capital expenditure requirements into the second quarter of 2027, assuming only preliminary work for a Phase 2b trial of GRI-0621 . Substantial additional capital is required to complete a Phase 2b clinical trial of GRI-0621, and the company intends to complete IND-enabling studies and file an IND application for GRI-0803 to initiate Phase 1a and 1b trials in 2026, initially focusing on lupus . The company plans to raise additional capital through equity issuances, debt, and potential strategic partnerships, acknowledging substantial doubt about its ability to continue as a going concern without further funding . ### Related Stocks - [GRI.US](https://longbridge.com/en/quote/GRI.US.md) ## Related News & Research - [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md) - [GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase | GRI Stock News](https://longbridge.com/en/news/286777671.md) - [VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News](https://longbridge.com/en/news/286964504.md) - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [Valion Bio Reports Q1 Results, Advances Entolimod Platform](https://longbridge.com/en/news/286477206.md)